Mariaelena Valentino

Mariaelena Valentino

Auto-generated profile, based on publicly available information

Mariaelena Valentino

IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, 20139, Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMatteo Malinverno
Matteo Malinverno
CMClaudio Maderna
Claudio Maderna
ATAbdallah Abu Taha
Abdallah Abu Taha
MCMonica Corada
Monica Corada
FOFabrizio Orsenigo
Fabrizio Orsenigo
EDElisabetta Dejana
Elisabetta Dejana
Cerebral cavernous malformation (CCM) is a neurovascular familial or sporadic disease that is characterised by capillary-venous cavernomas, and is due to loss-of-function mutations to any one of three CCM genes. Familial CCM follows a two-hit mechanism similar to that of tumour suppressor genes, while in sporadic cavernomas only a small fraction of endothelial cells shows mutated CCM genes. We reported that in mouse models and in human patients, endothelial cells lining the lesions have different features from the surrounding endothelium, as they express mesenchymal/stem-cell markers. Here we show that cavernomas originate from clonal expansion of few Ccm3-null endothelial cells that express mesenchymal/stem-cell markers. These cells then attract surrounding wild-type endothelial cells, inducing them to express mesenchymal/stem-cell markers and to contribute to cavernoma growth. These characteristics of Ccm3-null cells are reminiscent of the tumour-initiating cells that are responsible for tumour growth. Our data support the concept that CCM has benign tumour characteristics.

30 December 2020 in Genes & Diseases
Verified
Journal Article
Open access
MVMariaelena Valentino
Mariaelena Valentino
EDElisabetta Dejana
Elisabetta Dejana
MMMatteo Malinverno
Matteo Malinverno
The programmed cell death 10 (PDCD10) gene was originally identified as an apoptosis-related gene, although it is now usually known as CCM3, as the third causative gene of cerebral cavernous malformation (CCM). CCM is a neurovascular disease that is characterized by vascular malformations and is associated with headaches, seizures, focal neurological deficits, and cerebral hemorrhage. The PDCD10/CCM3 protein has multiple subcellular localizations and interacts with several multi-protein complexes and signaling pathways. Thus PDCD10/CCM3 governs many cellular functions, which include cell-to-cell junctions and cytoskeleton organization, cell proliferation and apoptosis, and exocytosis and angiogenesis. Given its central role in the maintenance of homeostasis of the cell, dysregulation of PDCD10/CCM3 can result in a wide range of altered cell functions. This can lead to severe diseases, including CCM, cognitive disability, and several types of cancers. Here, we review the multifaceted roles of PDCD10/CCM3 in physiology and pathology, with a focus on its functions beyond CCM.

6 November 2019 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
LPLoredana Poeta
Loredana Poeta
APAgnese Padula
Agnese Padula
BABenedetta Attianese
Benedetta Attianese
MVMariaelena Valentino
Mariaelena Valentino
LVLucia Verrillo
Lucia Verrillo
Maria Giuseppina MianoMaria Giuseppina Miano
Maria Giuseppina Miano
A disproportional large number of neurodevelopmental disorders (NDDs) is caused by variants in genes encoding transcription factors and chromatin modifiers. However, the functional interactions between the corresponding proteins are only partly known. Here, we show that KDM5C, encoding a H3K4 demethylase, is at the intersection of transcriptional axes under the control of three regulatory proteins ARX, ZNF711 and PHF8. Interestingly, mutations in all four genes (KDM5C, ARX, ZNF711 and PHF8) are associated with X-linked NDDs comprising intellectual disability as a core feature. in vitro analysis of the KDM5C promoter revealed that ARX and ZNF711 function as antagonist transcription factors that activate KDM5C expression and compete for the recruitment of PHF8. Functional analysis of mutations in these genes showed a correlation between phenotype severity and the reduction in KDM5C transcriptional activity. The KDM5C decrease was associated with a lack of repression of downstream target genes Scn2a, Syn1 and Bdnf in the embryonic brain of Arx-null mice. Aiming to correct the faulty expression of KDM5C, we studied the effect of the FDA-approved histone deacetylase inhibitor suberanilohydroxamic acid (SAHA). In Arx-KO murine ES-derived neurons, SAHA was able to rescue KDM5C depletion, recover H3K4me3 signalling and improve neuronal differentiation. Indeed, in ARX/alr-1-deficient Caenorhabditis elegans animals, SAHA was shown to counteract the defective KDM5C/rbr-2-H3K4me3 signalling, recover abnormal behavioural phenotype and ameliorate neuronal maturation. Overall, our studies indicate that KDM5C is a conserved and druggable effector molecule across a number of NDDs for whom the use of SAHA may be considered a potential therapeutic strategy.

14 October 2024 in EMBO Molecular Medicine
Verified
Journal Article
Open access
VPVan-Cuong Pham
Van-Cuong Pham
CRClaudia Jasmin Rödel
Claudia Jasmin Rödel
MVMariaelena Valentino
Mariaelena Valentino
MMMatteo Malinverno
Matteo Malinverno
APAlessio Paolini
Alessio Paolini
SASalim Abdelilah-Seyfried
Salim Abdelilah-Seyfried
Cerebral cavernous malformations (CCMs) are anomalies of the cerebral vasculature. Loss of the CCM proteins CCM1/KRIT1, CCM2, or CCM3/PDCD10 trigger a MAPK-Krüppel-like factor 2 (KLF2) signaling cascade, which induces a pathophysiological pattern of gene expression. The downstream target genes that are activated by KLF2 are mostly unknown. Here we show that Chromobox Protein Homolog 7 (CBX7), component of the Polycomb Repressive Complex 1, contributes to pathophysiological KLF2 signaling during zebrafish cardiovascular development. CBX7 / cbx7a mRNA is strongly upregulated in lesions of CCM patients, and in human, mouse, and zebrafish CCM-deficient endothelial cells. The silencing or pharmacological inhibition of CBX7/Cbx7a suppresses pathological CCM phenotypes in ccm2 zebrafish, CCM2-deficient HUVECs, and in a pre-clinical murine CCM3 disease model. Whole-transcriptome datasets from zebrafish cardiovascular tissues and human endothelial cells reveal a role of CBX7/Cbx7a in the activation of KLF2 target genes including TEK , ANGPT1 , WNT9 , and endoMT-associated genes. Our findings uncover an intricate interplay in the regulation of Klf2-dependent biomechanical signaling by CBX7 in CCM. This work also provides insights for therapeutic strategies in the pathogenesis of CCM.

27 August 2024 in Circulation
Verified
Journal Article
Closed access
MVMariaelena Valentino
Mariaelena Valentino
MMMatteo Malinverno
Matteo Malinverno
CMClaudio Maderna
Claudio Maderna
VPVan-Cuong Pham
Van-Cuong Pham
CRClaudia Jasmin Rödel
Claudia Jasmin Rödel
MPMassimiliano Pagani
Massimiliano Pagani